Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

Eph receptors have emerged as targets for therapy in both neoplastic and non-neoplastic disease, however, particularly in non-neoplastic diseases, redundancy of function limits the effectiveness of targeting individual Eph proteins. We have shown previously that a soluble fusion protein, where the E...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegg, Cassandra L., Cooper, Leanne T., Zhao, Jing, Gerometta, Michael, Smith, Fiona M., Yeh, Michael, Bartlett, Perry F., Gorman, Jeffrey J., Boyd, Andrew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529513/
https://www.ncbi.nlm.nih.gov/pubmed/28747680
http://dx.doi.org/10.1038/s41598-017-06685-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529513/
https://www.ncbi.nlm.nih.gov/pubmed/28747680
http://dx.doi.org/10.1038/s41598-017-06685-z

Ejemplares similares